Human Microbiome Market

Enterome Bioscience (France) and Seres Therapeutics (US) are Leading Players in the Human Microbiome Market

The human microbiome market is expected to grow from USD 942 million in 2024 to USD 1,731 million by 2027, at a CAGR of 22.5% during 2024–2027. The human microbiome field is a rapidly emerging area of biology and offers new routes for personalized healthcare strategies, improved nutrition, animal welfare, and industrial products. Owing to this, the applications of microbiome research are growing at a significant rate.

The major players in the human microbiome market include Enterome Bioscience (France), E.I. du Pont de Nemours and Company (DuPont) (US), 4D Pharma (UK), and Seres Therapeutics (US). Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.

To know about the assumptions considered for the study download the pdf brochure

Enterome Bioscience (France) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. In 2018, the company raised USD 38.5 million (EUR 32 million) in a Series D financing, which will be used for clinical trials of Enterome’s lead development programs, namely, Phase 2 study of the company’s oral FimH blocker EB8018 for the treatment of Crohn’s disease and Phase 1b study of EO2315, a novel immuno-oncology candidate, in patients with aggressive brain cancer (glioblastoma multiforme). Moreover, the company received a loan facility of USD 44.3 million (EUR 40 million) from the European Investment Bank (EIB) to support the acceleration of its pipeline and technology development. Such financing will help the company to conduct research on its microbiome-based products.

Seres Therapeutics (US) is one of the emerging players operating in this market. Its is engaged in developing a range of novel therapeutic products based on the human microbiome. The company’s microbiome therapeutics platform allows to significantly reduce the time typically required to advance therapeutics to the clinic, and ultimately, to the market. The company focuses on R&D to launch advanced products in the market. In 2017, the company invested 278% of its total revenue in R&D activities.

Related Reports:

Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
BT 2711
RI Published ON
9/3/2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Human Microbiome Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved